A Long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's Disease Participants
NCT02337764
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
222
Enrollment
INDUSTRY
Sponsor class
Conditions
Parkinson's Disease
Interventions
DRUG:
TVP-1012 1mg
Sponsor
Takeda